FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
University of Birmingham
1,672 participants
Sep 17, 2020
INTERVENTIONAL
Conditions
Summary
FaR-RMS is an over-arching study for children and adults with newly diagnosed and relapsed rhabdomyosarcoma (RMS)
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
antineoplastic enzyme inhibitor
Antineoplastic agent that is a polypeptide antibiotic
An anthracycline topoisomerase inhibitor isolated from streptpmyces peucetius var. casesius
chemotherapeutic agent chemically related to the nitrogen mustards and is a synthetic analog of cyclophosphamide
anti neoplastic vinca alkaloid agent
vinca alkaloid with a role as an antineoplastic agent
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent
oral antineoplastic alkylating agent
Ionising radiation
Oral multi-kinase inhibitor that targets a broad range of angiogenic, stromal and oncogenic kinases, including vascular endothelial growth factor receptors (VEFGR) 1, 2 and 3, tyrosine kinase with immunoglobulin and epidermal growth factor homology domain 2 (TIE2), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptors (FGFR), c-KIT, RET, RAF-1 and BRAF (wild-type and V600E mutant).
Locations(128)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04625907